So far, different CD44 splice variants have been described to affect tumorigenesis, cancer stemness and drug resistance [11,12,13], e.g., CD44v3 promotes progression of urothelial carcinomas through AKT/ERK/STAT3 pathways [14]. This evidence concerns the gene CD44 and cancer.